Sec Form 4/A Filing - Currie Mark G @ Cyclerion Therapeutics, Inc. - 2019-04-01

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4/A
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Currie Mark G
2. Issuer Name and Ticker or Trading Symbol
Cyclerion Therapeutics, Inc. [ CYCN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
President
(Last) (First) (Middle)
C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET
3. Date of Earliest Transaction (MM/DD/YY)
04/01/2019
(Street)
CAMBRIDGE, MA02142
4. If Amendment, Date Original Filed (MM/DD/YY)
04/03/2019
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $ 12.24 ( 1 ) 04/01/2019 A 37,279 ( 2 ) 02/01/2021 Common Stock 37,279 $ 0 37,279 ( 3 ) D
Employee Stock Option (Right to Buy) $ 16.21 04/01/2019 A 1 7,490 ( 2 ) 02/01/2022 Common Stock 17,490 $ 0 17,490 ( 3 ) D
Employee Stock Option (Right to Buy) $ 14.4 04/01/2019 A 27,772 ( 2 ) 02/01/2023 Common Stock 27,772 $ 0 27,772 ( 3 ) D
Employee Stock Option (Right to Buy) $ 17.2 04/01/2019 A 2,500 ( 4 ) 03/01/2025 Common Stock 2,500 $ 0 2,500 ( 4 ) D
Employee Stock Option (Right to Buy) $ 11.28 04/01/2019 A 50,794 ( 5 ) 03/01/2026 Common Stock 50,794 $ 0 50,794 ( 3 ) D
Employee Stock Option (Right to Buy) $ 18.47 ( 1 ) 04/01/2019 A 113,413 ( 6 ) 02/27/2027 Common Stock 113,413 $ 0 113,413 ( 3 ) D
Employee Stock Option (Right to Buy) $ 16.02 04/01/2019 A 140,984 ( 7 ) 02/21/2028 Common Stock 140,984 $ 0 140,984 ( 3 ) D
Employee Stock Option (Right to Buy) $ 14.21 ( 1 ) 04/01/2019 A 514,698 ( 8 ) 01/29/2029 Common Stock 514,698 $ 0 514,698 ( 3 ) D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Currie Mark G
C/O CYCLERION THERAPEUTICS, INC.
301 BINNEY STREET
CAMBRIDGE, MA02142
President
Signatures
/s/ Larry Miller, Attorney-in-Fact 09/20/2019
Signature of Reporting Person Date
Explanation of Responses:
( 1 )This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 ("the Separation").
( 2 )This option, granted as an annual performance award, is presently exercisable in full.
( 3 )This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation.
( 4 )This footnote has been amended to reflect the number of unvested options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. This option to purchase 25,208 shares vests in equal installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,500 shares as of the date hereof.
( 5 )The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2016.
( 6 )The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2017.
( 7 )The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2018.
( 8 )The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2019.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.